Is Scholar Rock Holding (SRRK) Offering Value After Its Strong Multi Year Share Price Gains

• Wondering if Scholar Rock Holding at around US$46.45 is giving you fair value or a potential opportunity? This article walks through the key numbers in plain language so you can judge for yourself.
• The stock has seen mixed recent returns, with a 0.3% decline over the last 7 days and a 6.9% decline over the last month, alongside gains of 8.5% year to date, 49.9% over 1 year and a very large 3 year return, plus a 63.3% gain over 5 years.
• These moves have come as investors weigh ongoing developments in Scholar Rock Holding's drug pipeline and its position within the biotech sector, alongside changing risk appetite for high growth healthcare stocks. Together, these themes help explain why the share price has been more volatile recently.
• On Simply Wall St's valuation checks, Scholar Rock Holding scores 3 out of 6. The rest of this article breaks down what different valuation methods say about the stock, and then finishes with a more complete way to think about value that goes beyond any single model.

Scholar Rock Holding delivered 49.9% returns over the last year. See how this stacks up to the rest of the Biotechs industry.

Approach 1: Scholar Rock Holding Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a stock might be worth by projecting the company’s future cash flows and then discounting those back to today’s value.

For Scholar Rock Holding, the latest twelve month free cash flow (FCF) is a loss of $300.64 million. Analysts and internal estimates project FCF gradually turning positive over time, reaching $218.25 million in 2030. Between 2026 and 2035, Simply Wall St uses a 2 Stage Free Cash Flow to Equity model. This combines analyst estimates for the earlier years with extrapolated figures for the later years.

When all those projected cash flows are discounted back to today, the model arrives at an estimated intrinsic value of about $157.25 per share. Against a recent share price around $46.45, this implies the stock is roughly 70.5% undervalued on this specific DCF view.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Scholar Rock Holding is undervalued by 70.5%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Scholar Rock Holding.

Approach 2: Scholar Rock Holding Price vs Book

For profitable companies with meaningful balance sheets, the P/B ratio helps you see how the market values each dollar of net assets. It is especially useful in asset heavy or research intensive sectors where current earnings may not fully reflect the business.

What investors are willing to pay for a given P/B ratio often reflects growth expectations and risk. Higher growth and lower perceived risk can justify a higher multiple, while slower growth or higher uncertainty can point to a lower one as “normal” for the stock.

Scholar Rock Holding currently trades on a P/B of 20.08x. That is well above the Biotechs industry average of 2.39x and also above the peer group average of 13.35x. Simply Wall St’s Fair Ratio framework goes a step further by estimating what a more tailored P/B might look like after factoring in earnings growth, profit margins, industry, market cap and company specific risks.

This Fair Ratio approach can be more informative than a simple comparison with peers or the broad industry, because two companies with the same raw P/B can have very different growth, risk and profitability profiles. In this case, the actual P/B of 20.08x sits above the Fair Ratio, which indicates that the stock may be trading at a relatively high level on this measure.

Result: OVERVALUED

P/B ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Scholar Rock Holding Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St’s Community page give you a clear story behind your own numbers by linking your view of Scholar Rock Holding’s pipeline, revenue potential and margins to a forecast and fair value. These narratives update automatically as news or earnings arrive and let you compare your chosen fair value with today’s price. This is why one investor might build a bullish narrative closer to the US$70 analyst target, while another prefers a more cautious view around US$47.

Do you think there's more to the story for Scholar Rock Holding? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com